Reimbursement Pathways for Psychedelic Therapies

Welcome to Reimbursement Pathways for Psychedelic Therapies, the podcast that investigates how psychedelics become reimbursed care. I’m Floris Wolswijk, project manager at Delphi and founder of Blossom, and I'm on a journey to investigate how we can get psychedelics to become a part of mainstream healthcare. Each month, I'll interview health economists, payers, drug developers, and policy...

Welcome to the final chapter of our series on psychedelic therapies in Europe. This episode moves beyond the regulatory and reimbursement pathways discussed in previous chapters to present critical observations from various experts. First, Martin Gisby from Magnetar Access shares his perspective on commercial strategies and reimbursement. He highlights the importance of focusing on smaller patient...

In the penultimate episode of our series on the psychedelic therapy landscape, we explore the practical aspects of reimbursement for psychedelic therapies across Europe. We cover nine different potential pathways, from discussing standard national reimbursement pathways and their limitations to examining modified assessment methods. These include private insurance care, out-of-pocket payments, inn...

In Chapter 9 of our series on psychedelic therapies and reimbursement, we discuss the critical challenge of ensuring equitable access. With psychedelic therapies nearing approval in Europe, disparities in access based on income, schedule flexibility, and healthcare connections are evident. This episode highlights the underrepresentation of ethnic minorities, immigrants, and economically disadvanta...

In the eighth episode, we take the opposite perspective from our discussion in the last episode on the challenges surrounding psychedelic therapies in Europe. This time, we focus on practical solutions for integrating these therapies into European healthcare systems, presented in Chapter 8: Solutions and Recommendations. We explore strengthening clinical evidence, enhancing economic evaluations, i...

In this episode, we explore Chapter 7: Challenges and Barriers to Reimbursement for psychedelic therapies across Europe. We discuss the complex process of getting these treatments approved and covered by healthcare systems, focusing on the unique issues that arise from their combined use of drugs and structured psychotherapeutic support. Key points include clinical trial design limitations, eviden...

In this episode, we move into Chapter 6: Mapping the Reimbursement Landscape in Europe. This chapter explains how the funding systems work in various European countries, highlighting the challenges for new therapies, particularly psychedelics. We discuss the reimbursement processes in Germany, the UK, the Netherlands, and the Czech Republic, detailing how each system handles pricing, national eval...

In Chapter 5, we examine the essential process of securing patient access to psychedelic therapies post-regulatory approval by working with Payer and Health Technology Assessment (HTA) bodies. The chapter discusses the importance of demonstrating clinical efficacy through direct comparisons and indirect comparisons when head-to-head trials aren't feasible. It explains how different European co...

In this episode about Chapter 4, we focus on the Clinical Development of Psychedelic Therapies. We'll explore the fast-evolving clinical landscape, especially in the US, and compare it with Europe where regulatory and clinical frameworks are still forming. Key topics include designing and conducting clinical trials, addressing challenges like functional unblinding and comparator selection, and...

In this episode, we explore Chapter 3 of our report on psychedelics and reimbursement, focusing on the drug development and reimbursement pathway in Europe. We cover the journey from drug discovery and preclinical development through clinical trials, regulatory approval, and the negotiation of pricing and reimbursement. Special considerations for controlled substances and psychedelic therapies are...

In Chapter 2 of our series on psychedelic therapies in Europe, we explore the foundational introduction to psychedelics, their history, therapeutic potential, and the current reimbursement landscape. We look into the ancient uses of psychedelics in different cultures, the mid-20th century research surge and subsequent societal backlash, and the modern resurgence driven by new scientific interest....

Welcome to the first chapter of our in-depth look at the future of mental healthcare in Europe, focusing on the promise and challenges of psychedelic therapies. This episode dives into the Executive Summary of our comprehensive report, discussing the potential of these therapies to revolutionise treatment for mental health disorders such as depression, PTSD, and addictions. We cover key findings f...